Trephine
AboutSpecialtiesPricingLoading...

Copyright © 2024 Trephine. All rights reserved. The content of this site is intended for health care professionals.

TREPHINE

Terms Of UsePrivacy Policy

Lancet (London, England)Review

28 Jun 2025

Understanding the drivers and consequences of early-onset type 2 diabetes.

Abstract

Early-onset type 2 diabetes (defined as type 2 diabetes diagnosed in people aged <40 years) is increasingly prevalent with substantial health and socioeconomic implications.

Unlike late-onset type 2 diabetes, early-onset type 2 diabetes is a high-risk and aggressive phenotype, with accelerated pancreatic β-cell decline and greater insulin resistance due to the rising rate of obesity.

People with early-onset type 2 diabetes have higher rates of macrovascular and microvascular complications with increased health-care use and premature mortality (due to cardiovascular and non-cardiovascular complications) than do people with late-onset type 2 diabetes.

Emerging evidence also suggests that people with early-onset type 2 diabetes face an increased risk of complications in reproductive health (eg, during periconception and postpartum periods), metabolic-associated steatotic liver disease, mental health (eg, diabetes distress, depression, anxiety, and psychotic disorders), and some cancers, creating additional challenges in managing multiple long-term conditions.

In this Series paper, we highlight the consequences of early-onset type 2 diabetes and the key driver for these risks-long duration of exposure to hyperglycaemia, with its effects amplified by younger age at type 2 diabetes diagnosis and interactions with other cardiometabolic risk factors.

Recognising these adverse risks associated with early-onset type 2 diabetes is crucial for guiding the development and implementation of a more focused and integrated life-course approach to mitigate its long-term effect on individuals, communities, and health-care systems globally.

However, substantial research gaps remain that must be addressed, particularly in diverse populations.

COI Statement

Declaration of interests L-LL has received research grants via her institution from Abbott Diabetes Care, AstraZeneca, and Novartis; and speaker honoraria from Abbott, AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Roche Diabetes Care, and Zuellig Pharma. SM has received speaker honoraria from Lilly UK, Sanofi, and Menarini. All other authors declare no competing interests.

Article info

Journal issue:

  • Volume: 405
  • Issue: 10497

Doi:

10.1016/S0140-6736(25)01012-8

More resources:

Elsevier Science

Full Text Sources

Paid

MedlinePlus Health Information

Medical

Free resource

ClinicalKey

Full Text Sources

Paid

Share: